Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07519187) titled 'CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms' on April 2.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The General Hospital of Western Theater Command

Condition: Relapsed or Refractory Plasma Cell Neoplasms

Intervention: Genetic: CAR 70-BCMA CAR-T

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: April 3, 2026

Target Sample Size: 20

Countries of Recruitment: China

To know more, visit https://clin...